Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD KesimptaⓇ - CD20 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03650114 ALITHIOS (COMB157G2399) Multiple Sclerosis Phase 3 2010 Evaluate the long-term safety and tolerability of ofatumumab 20 mg subcutaneous (sc) once every 4 (94) weeks in subjects with RMS from the first dose of ofatumumab Ofatumumab 20 mg every 4 weeks Patients with relapsing MS Target Patients Read-out Milesstone(s) Publication 2028 TBD 89 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation